$66.1 Million is the total value of Kazazian Asset Management, LLC's 52 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 187.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EEM | New | ISHARES TRmsci emg mkt etf | $8,071,000 | – | 195,000 | +100.0% | 12.22% | – |
| CLNS | Buy | COLONY NORTHSTAR INC | $6,218,000 | +16.6% | 441,271 | +6.9% | 9.41% | +27.5% |
| GM | Buy | GENERAL MTRS CO | $6,190,000 | +7.9% | 177,204 | +9.2% | 9.37% | +18.0% |
| EWG | New | ISHARESmsci germany etf | $1,665,000 | – | 55,000 | +100.0% | 2.52% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $1,179,000 | – | 23,273 | +100.0% | 1.78% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $1,055,000 | – | 11,264 | +100.0% | 1.60% | – |
| GDX | Buy | VANECK VECTORS ETF TRgold miners etf | $969,000 | +27.3% | 43,881 | +31.5% | 1.47% | +39.2% |
| EWZ | New | ISHARESmsci brz cap etf | $888,000 | – | 26,000 | +100.0% | 1.34% | – |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $847,000 | +41.2% | 15,207 | +37.9% | 1.28% | +54.3% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $818,000 | +72.9% | 6,723 | +72.4% | 1.24% | +89.0% |
| SALT | Buy | SCORPIO BULKERS INC | $513,000 | -7.6% | 72,315 | +19.9% | 0.78% | +1.0% |
| GREK | New | GLOBAL X FDSmsci greece etf | $506,000 | – | 50,000 | +100.0% | 0.77% | – |
| AERI | New | AERIE PHARMACEUTICALS INC | $450,000 | – | 8,558 | +100.0% | 0.68% | – |
| MRK | New | MERCK & CO INC | $439,000 | – | 6,848 | +100.0% | 0.66% | – |
| JUNO | New | JUNO THERAPEUTICS INC | $428,000 | – | 14,307 | +100.0% | 0.65% | – |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $406,000 | +23.0% | 66,304 | +47.3% | 0.62% | +34.6% |
| UA | Buy | UNDER ARMOUR INCcl c | $403,000 | +46.5% | 20,000 | +33.3% | 0.61% | +60.1% |
| SGEN | New | SEATTLE GENETICS INC | $354,000 | – | 6,848 | +100.0% | 0.54% | – |
| EIGI | New | ENDURANCE INTL GROUP HLDGS I | $316,000 | – | 37,847 | +100.0% | 0.48% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $311,000 | – | 3,424 | +100.0% | 0.47% | – |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $295,000 | – | 6,850 | +100.0% | 0.45% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $213,000 | – | 3,424 | +100.0% | 0.32% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $209,000 | – | 2,393 | +100.0% | 0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GENERAL MTRS CO | 20 | Q3 2019 | 9.4% |
| APPLE INC | 20 | Q3 2019 | 8.8% |
| CITIGROUP INC | 20 | Q3 2019 | 6.2% |
| ALIBABA GROUP HLDG LTD | 20 | Q3 2019 | 2.6% |
| EQUUS TOTAL RETURN INC | 20 | Q3 2019 | 0.1% |
| MECHEL PAO | 20 | Q3 2019 | 0.1% |
| GENERAL MOLY INC | 20 | Q3 2019 | 0.0% |
| GENERAL MTRS CO | 19 | Q2 2019 | 0.5% |
| SPDR S&P 500 ETF TR | 17 | Q3 2019 | 51.5% |
| BAIDU INC | 17 | Q3 2019 | 6.5% |
View Kazazian Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| GEE Group Inc. | February 14, 2022 | 182,555 | 0.2% |
| Bonds.com Group, Inc. | July 10, 2013 | 28,571 | 10.5% |
View Kazazian Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2022-02-14 |
| SC 13G | 2021-04-29 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-15 |
View Kazazian Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.